Mark Frost was named Chief Financial Officer of Harvard Bioscience Inc, effective March 6, 2026. As of November 14, 2026, Harvard Bioscience Inc has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on March 10, 2026, naming 1 appointment (Form 8-K, March 10, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Harvard Bioscience Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Harvard Bioscience Inc reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-03-10. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Harvard Bioscience Inc files it.
Layoffs on record: 1 filing or notice, latest 2026-01-29 (layoff filings and notices).
Also on the record for Harvard Bioscience Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 22, 2026 | Stake report, Schedule 13G/A, by Leviticus Partners LP | 5.2% of the class | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13G/A, by Leviticus Partners LP | 6.5% of the class | 5%+ stakes | Source |
| March 23, 2026 | Stake report, Schedule 13D, by William Snider | 15.97% of the class | 5%+ stakes | Source |
| February 12, 2026 | Stake report, Schedule 13G/A, by Leviticus Partners LP | 7.6% of the class | 5%+ stakes | Source |
| November 3, 2025 | Stake report, Schedule 13G/A, by Leviticus Partners LP | 7.5% of the class | 5%+ stakes | Source |
| August 7, 2025 | Stake report, Schedule 13G/A, by Leviticus Partners LP | 9.2% of the class | 5%+ stakes | Source |
| July 17, 2025 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 2.5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Harvard Bioscience Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Harvard Bioscience Inc and the records around it.
Harvard Bioscience Inc elsewhere on the record
- 5%+ stake filings Sep 2026
- Layoff notices Jan 2026
- Who owns it
Companies that share a holder
- Leviticus Partners LP also filed stake reports on 6 other companies: Maris Tech Ltd. (Sep 2026), SEQUANS COMMUNICATIONS (May 2026), UNIVERSAL ELECTRONICS INC (May 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
Watch Harvard Bioscience Inc
Get an email when Harvard Bioscience Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Harvard Bioscience Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Harvard Bioscience Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Harvard Bioscience Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-03-10 | In | Chief Financial Officer | 2026-03-06 | 8-K, 2026-03-10 |
Who leads Harvard Bioscience Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Mark Frost, appointed, effective 2026-03-06 (filed 2026-03-10).
New leaders reset buying decisions — get the Full Report on Harvard Bioscience Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Harvard Bioscience Inc, with the record behind each one.
Find candidates like Chief Financial Officer at Harvard Bioscience IncEvery change, in the filing's words
Appointed: Mark Frost, Chief Financial Officer, effective 2026-03-06
Appointment of Chief Financial Officer - Mark Frost Effective March 6, 2026, the Board of Directors of the Company appointed Mark Frost to serve as Chief Financial Officer and Treasurer of the Company.
- Compensatory Arrangements - John Duke On March 6, 2026, Harvard Bioscience, Inc. (the "Company") entered into an Amended and Restated Employment Agreement (the "Duke Employment Agreement") with John Duke, the Company's Chief Executive Officer.
- The Duke Employment Agreement supersedes and replaces that certain employment agreement entered into with Mr. Duke on July 16, 2025.
- The Duke Employment Agreement provides that Mr. Duke will receive an annual base salary of $515,000, subject to annual review beginning in 2027.
- The term of the Duke Employment Agreement is extended until July 16, 2027, and it shall automatically be extended for two additional years following the end of the term then in effect, subject to terms in the Duke Employment Agreement.
- In lieu of the annual bonus for fiscal year 2025, Mr. Duke will be eligible to be paid a cash bonus in the gross amount of $100,000, less applicable deductions and withholdings, based on the successful refinancing of the Company's credit facility.
- Mr. Duke will also be eligible to receive annual cash incentive compensation of up to 80% of his base salary, payable upon meeting objectives as determined by the Board or a committee thereof, from time to time in their sole discretion.
- In fiscal year 2026, Mr. Duke shall be eligible to receive annual equity grants, in the sole discretion of the Board or a committee thereof.
Tools for this story
Each opens in a new tab, filled in for Harvard Bioscience Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
